Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xaluritamig vs Cabazitaxel or Second ARDT in mCRPC
NCT06691984Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2024
- Primary completion
- Jan 2029
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of xaluritamig in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Amgen. Primary endpoint: Overall Survival at 53 months. Started Dec 2024; status: active, not recruiting.
02
Drugs
xaluritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06691984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06691984.